Extended Use of Automated Insulin Delivery in Young People with Type 1 Diabetes and Elevated HbA1c: 52-Week Outcomes of the CO-PILOT Trial.

Key Points

• To assess the long-term effects of automated insulin delivery on glycemia in young people with type 1 diabetes and high HbA1c levels.
• Conducted a 52-week trial with young individuals diagnosed with type 1 diabetes.
• Utilized automated insulin delivery system MM780G for glycemic management.
• Monitored HbA1c levels and overall safety throughout the trial.
• Significant and sustained reductions in HbA1c levels were observed over the 52 weeks.
• Improvements in glycemia were noted without any safety concerns reported.
• Support for broader adoption of automated insulin delivery systems in high-risk youth.